SEARCH

SEARCH BY CITATION

References

  • 1
    Chabbert-Buffet N, A Pintiaux A, Bouchard P. The imminent dawn of SPRMs in obstetrics and gynecology. Mol Cell Endocrinol 2012;358:23243.
  • 2
    Wilkens J, Critchley H. Progesterone receptor modulators in gynaecological practice. J Fam Plann Reprod Health Care 2010;36:8792.
  • 3
    Chwalisz K, Perez MC, DeManno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Reviews 2005;26:42338.
  • 4
    Bouchard P, Chabbert-Buffet N, Fauser BC. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril 2011;96:117589.
  • 5
    Concise Medical Dictionary. 8th ed. Oxford: Oxford University Press; 2010.
  • 6
    National Institute for Health and Care Excellence. Uterine artery embolisation for fibroids (IPG367). London: National Institute for Health and Care Excellence; 2010.
  • 7
    Kim JJ, Kurita T, Bulun SE. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev. 2013;34:13062.
  • 8
    Catherino WH, Malik M, Driggers P, Chappel S, Segars J, Davis J. Novel, orally active selective progesterone receptor modulator CP8947 inhibits leiomyoma cell proliferation without adversely affecting endometrium or myometrium. J Steroid Biochem Mol Biol 2010;122:27986.
  • 9
    The Royal College of Radiologists and the Royal College of Obstetricians and Gynaecologists. Clinical recommendations on uterine artery embolisation in the management of fibroids Second edition. London: The Royal College of Radiologists, 2009 [http://www.rcr.ac.uk/docs/radiology/pdf/BFCR%2809%291_Embolisation.pdf].
  • 10
    National Institute for Health and Care Excellence. Heavy Menstrual Bleeding. (CG44) London: National Institute for Health and Care Excellence;2007.
  • 11
    Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev 2000;(2):CD000547.
  • 12
    Leather AT, Studd JW, Watson NR, Holland EF. The prevention of bone loss in young women treated with GnRH analogues with “add-back” estrogen therapy. Obstet Gynecol 1993;81:1047.
  • 13
    Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012;366:40920.
  • 14
    Donnez J, Tomaszewski J, Vázquez F, Bouchard P, Lemieszczuk B, Baró F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366:42132.
  • 15
    Faculty of Sexual and Reproductive Healthcare. Statement on drug interactions between hormonal contraception and ulipristal products: ellaOne® and Esmya ®. London: Faculty of Sexual and Reproductive Health;2012[http://www.fsrh.org/pdfs/CEUstatementEsmya.pdf].
  • 16
    Electronic Medicines Compendium (ePC). Summary of product characteristics: Esmya 5 mg tablets (ulipristal acetate) [http://www.medicines.org.uk/EMC/medicine/26068/SPC/2012].
  • 17
    Faculty of Sexual and Reproductive Healthcare. Emergency contraception: clinical guidance. London: Faculty of Sexual and Reproductive Healthcare; 2012 [http://www.fsrh.org/pdfs/CEUguidanceEmergencyContraception11.pdf].
  • 18
    Kulier R, Kapp N, Gülmezoglu AM, Hofmeyr GJ, Cheng L, Campana A. Medical methods for first trimester abortion. Cochrane Database Syst Rev 2011;(11):CD002855.
  • 19
    Brown A, Cheng L, Lin S, Baird DT. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab 2002;87:6370.
  • 20
    Glasier AF, Cameron ST, Fine PM, Logan SJ, Casale W, Van Horn J, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet 2010;375:55562.
  • 21
    Cheng L, Che Y, Gülmezoglu AM. Interventions for emergency contraception. Cochrane Database Syst Rev 2012;(8):CD001324.
  • 22
    Faculty of Sexual and Reproductive Healthcare. Progesterone-only pills: clinical guidance London: Faculty of Sexual and Reproductive Healthcare; 2009 [http://www.fsrh.org/pdfs/CEUGuidanceProgestogenOnlyPill09.pdf].
  • 23
    Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W, Winkel CA. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 2007;87:1399412.
  • 24
    Hapangama DK, Brown A. Glasier AF, Baird DT. Feasibility of administering mifepristone as a once a month contraceptive pill. Hum Reprod 2001;16:114550.
  • 25
    Royal College of Obstetricians and Gynaecologists. The Investigation and management of endometriosis. Green-top guideline No.24. London: RCOG; 2008
  • 26
    Kettel LM, Murphy AA, Morales AJ, Ulmann A, Baulieu EE, Yen SS. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril 1996;65:238.
  • 27
    Mutter GL, Bergeron C, Deligdisch L, Ferenczy A, Glant M, Merino M, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008;21:5918.
  • 28
    Williams AR, Bergeron C, Barlow DH, Ferenczy A. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol 2012;31:55669.